Black Diamond Therapeutics ($BDTX)

BDTX Overview

Black Diamond Therapeutics, a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies.Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase.The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases.The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts. (From: StockAnalysis.com)

MORE ABOUT Black Diamond Therapeutics

Stay up to date with the best of Bullish each week.


Stay up to date with the best of Bullish each week.